Vimarsana
Biggest News Aggregation in the World

Shitara News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Shitara. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Shitara Today - Breaking & Trending Today

U.S. FDA ACKNOWLEDGES ASTELLAS' RESUBMISSION OF BIOLOGICS LICENSE APPLICATION FOR ZOLBETUXIMAB AND SETS NEW ACTION DATE - Vimarsana News

U.S. FDA ACKNOWLEDGES ASTELLAS' RESUBMISSION OF BIOLOGICS LICENSE APPLICATION FOR ZOLBETUXIMAB AND SETS NEW ACTION DATE

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA)...

'My Mother's Eyes' Salem Horror Fest 2024 Review - Vimarsana News

'My Mother's Eyes' Salem Horror Fest 2024 Review

Eye trauma and twisted family dynamics meet in the Japanese horror thriller 'My Mother's Eyes'. Read Sharai Bohannon's review.

Orchid without bumblebee on island finds wasp, loses self | Kobe University News site - Vimarsana News

Orchid without bumblebee on island finds wasp, loses self | Kobe University News site

Because the bumblebee that an orchid relies on for pollination does not exist on a remote island, th...

China's National Medical Products Administration Accepts Astellas' Biologics License Application for Zolbetuximab - Astellas Pharma (OTC:ALPMY) - Vimarsana News

China's National Medical Products Administration Accepts Astellas' Biologics License Application for Zolbetuximab - Astellas Pharma (OTC:ALPMY)

TOKYO, July 31, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products

China's National Medical Products Administration Accepts Astellas' Biologics License Application for Zolbetuximab - Vimarsana News

China's National Medical Products Administration Accepts Astellas' Biologics License Application for Zolbetuximab

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the Center for Drug Evaluation (CDE) of the...